Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations
Epistemonikos ID: 9484e8786145b7df4fa66aa0c91038a28c40b9e4
First added on: Jun 18, 2025